Market concentration of new antibiotic sales

doi:10.1038/s41429-021-00414-5

. 2021 Jun;74(6):421-423.

doi: 10.1038/s41429-021-00414-5. Epub 2021 Mar 4.

Market concentration of new antibiotic sales

Sakib Rahman¹, Olof Lindahl², Chantal M Morel^{2

3

4}, Aidan Hollis⁵

Affiliations

¹ Department of Economics, University of Calgary, Calgary, AB, Canada.
² Department of Business Studies, Uppsala University, Kyrkogårdsgatan, Uppsala, Sweden.
³ University Hospital Bonn, Institute for Hygiene and Public Health, Bonn, Germany.
⁴ University of Geneva Global Studies Institute, Geneva, Switzerland.
⁵ Department of Economics, University of Calgary, Calgary, AB, Canada. ahollis@ucalgary.ca.

PMID: 33664435
DOI: 10.1038/s41429-021-00414-5

Market concentration of new antibiotic sales

Sakib Rahman et al. J Antibiot (Tokyo). 2021 Jun.

. 2021 Jun;74(6):421-423.

doi: 10.1038/s41429-021-00414-5. Epub 2021 Mar 4.

Authors

Sakib Rahman¹, Olof Lindahl², Chantal M Morel^{2

3

4}, Aidan Hollis⁵

Affiliations

¹ Department of Economics, University of Calgary, Calgary, AB, Canada.
² Department of Business Studies, Uppsala University, Kyrkogårdsgatan, Uppsala, Sweden.
³ University Hospital Bonn, Institute for Hygiene and Public Health, Bonn, Germany.
⁴ University of Geneva Global Studies Institute, Geneva, Switzerland.
⁵ Department of Economics, University of Calgary, Calgary, AB, Canada. ahollis@ucalgary.ca.

PMID: 33664435
DOI: 10.1038/s41429-021-00414-5

Abstract

We calculate the average sales of new antibiotics during their first 8 years on the market. The discounted net present value is only $240 m in total per antibiotic, well below costs of supplying these products. The reliance on the US for sales is striking: the US market accounts for 84% of sales during the first 8 years. These facts clarify the need for additional revenues, especially from other countries, to support incentives for the development of new antibiotics. Market entry rewards may be of particular value.

PubMed Disclaimer

Cited by

Shortage of essential antimicrobials: a major challenge to global health security.
Shafiq N, Pandey AK, Malhotra S, Holmes A, Mendelson M, Malpani R, Balasegaram M, Charani E. Shafiq N, et al. BMJ Glob Health. 2021 Nov;6(11):e006961. doi: 10.1136/bmjgh-2021-006961. BMJ Glob Health. 2021. PMID: 34728479 Free PMC article. Review.
Antibiotics re-booted-time to kick back against drug resistance.
Blaskovich MAT, Cooper MA. Blaskovich MAT, et al. NPJ Antimicrob Resist. 2025 May 30;3(1):47. doi: 10.1038/s44259-025-00096-1. NPJ Antimicrob Resist. 2025. PMID: 40447846 Free PMC article. Review.
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.
Butler MS, Gigante V, Sati H, Paulin S, Al-Sulaiman L, Rex JH, Fernandes P, Arias CA, Paul M, Thwaites GE, Czaplewski L, Alm RA, Lienhardt C, Spigelman M, Silver LL, Ohmagari N, Kozlov R, Harbarth S, Beyer P. Butler MS, et al. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0199121. doi: 10.1128/AAC.01991-21. Epub 2022 Jan 10. Antimicrob Agents Chemother. 2022. PMID: 35007139 Free PMC article. Review.

References

1. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. (Review on Antimicrobial Resistance, 2016); http://amrreview.org/sites/default/files/160525_Final%20paper_with%20cov... . Last accessed 1 Nov 2020.
1. Årdal C, Balasegaram M, Laxminarayan R, McAdams D, Outterson K, Rex JH, et al. Antibiotic development — economic, regulatory and societal challenges. Nat Rev Microbiol. 2020;18:267–74. https://doi.org/10.1038/s41579-019-0293-3 . - DOI - PubMed
1. Outterson K. A shot in the arm for new antibiotics. Nat Biotechnol. 2019;37:1110–2. https://doi.org/10.1038/s41587-019-0279-8 . - DOI - PubMed
1. Simpkin VL, Renwick MJ, Kelly R, Mossialos E. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. J Antibiot. 2017;70:1087. - DOI
1. Krause K. Post-marketing commitments and Antimicrobial Susceptibility Test Development. ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. Boston, MA; 2019. https://www.youtube.com/watch?v=XYpUoQnxnXE . Last accessed 1 Nov 2020.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

pending/CIHR/Canada

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. (Review on Antimicrobial Resistance, 2016); http://amrreview.org/sites/default/files/160525_Final%20paper_with%20cov... . Last accessed 1 Nov 2020.

[2] O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. (Review on Antimicrobial Resistance, 2016); http://amrreview.org/sites/default/files/160525_Final%20paper_with%20cov... . Last accessed 1 Nov 2020.

[3] Årdal C, Balasegaram M, Laxminarayan R, McAdams D, Outterson K, Rex JH, et al. Antibiotic development — economic, regulatory and societal challenges. Nat Rev Microbiol. 2020;18:267–74. https://doi.org/10.1038/s41579-019-0293-3 . - DOI - PubMed

[4] Årdal C, Balasegaram M, Laxminarayan R, McAdams D, Outterson K, Rex JH, et al. Antibiotic development — economic, regulatory and societal challenges. Nat Rev Microbiol. 2020;18:267–74. https://doi.org/10.1038/s41579-019-0293-3 . - DOI - PubMed

[5] Outterson K. A shot in the arm for new antibiotics. Nat Biotechnol. 2019;37:1110–2. https://doi.org/10.1038/s41587-019-0279-8 . - DOI - PubMed

[6] Outterson K. A shot in the arm for new antibiotics. Nat Biotechnol. 2019;37:1110–2. https://doi.org/10.1038/s41587-019-0279-8 . - DOI - PubMed

[7] Simpkin VL, Renwick MJ, Kelly R, Mossialos E. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. J Antibiot. 2017;70:1087. - DOI

[8] Simpkin VL, Renwick MJ, Kelly R, Mossialos E. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. J Antibiot. 2017;70:1087. - DOI

[9] Krause K. Post-marketing commitments and Antimicrobial Susceptibility Test Development. ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. Boston, MA; 2019. https://www.youtube.com/watch?v=XYpUoQnxnXE . Last accessed 1 Nov 2020.

[10] Krause K. Post-marketing commitments and Antimicrobial Susceptibility Test Development. ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. Boston, MA; 2019. https://www.youtube.com/watch?v=XYpUoQnxnXE . Last accessed 1 Nov 2020.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Market concentration of new antibiotic sales

Affiliations

Market concentration of new antibiotic sales

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical